JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2005, 54(4):192-195

A Comparison of the Efficacy of the Reactivators of Acetylcholinesterase Inhibited with Tabun

J. Cabal, K. Kuča, D. Jun, J. Bajgar, M. Hrabinová
Univerzita obrany v Hradci Králové, Fakulta vojenského zdravotnictví, Katedra toxikologie

The nerve agent tabun inhibits acetylcholinesterase (AChE; EC 3.1.1.7) by the formation of a covalent bond with the enzyme. Afterwards, AChE is not able to fulfil its role in the organism and subsequently cholinergic crisis occurs. AChE reactivators (pralidoxime, obidoxime and HI-6) as causal antidotes are used for the cleavage of the bond between the enzyme and nerve agent. Unfortunately, their potency for reactivation of tabun-inhibited AChE is poor. The aim of the study was to choose the most potent reactivator of tabun-inhibited AChE. We have tested eight AChE reactivators - pralidoxime, obidoxime, trimedoxime, HI-6, methoxime, Hlö-7 and our newly synthesized oximes K027 and K048. All reactivators were tested using our standard in vitro reactivation test (pH 8, 25°C, time of inhibition by the nerve agent 30 minutes, time of reactivation by AChE reactivator 10 minutes). According to our results, only trimedoxime was able to achieve 50% reactivation potency. However, this relatively high potency was achieved at high oxime concentration (10-2 M). At a lower concentration of 10-4 M (the probably attainable concentration in vivo), four AChE reactivators (trimedoxime, obidoxime, K027, and K048) were able to reactivate AChE inhibited by tabun reaching from 10 to 18 %.

Keywords: acetylcholinesterase; reactivators; nerve agents; tabun; oxim

Received: January 19, 2005; Accepted: April 13, 2005; Published: April 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cabal J, Kuča K, Jun D, Bajgar J, Hrabinová M. A Comparison of the Efficacy of the Reactivators of Acetylcholinesterase Inhibited with Tabun. Čes. slov. farm. 2005;54(4):192-195.
Download citation

References

  1. Bajgar, J.: Adv. Clin. Chem., 2004; 38, 151. Go to original source... Go to PubMed...
  2. Marrs, T. C., Maynard, R. L., Sidell, F. R.: Chemical Warfare Agents. Chicester, Wiley & Sons, 1996, 293 s.
  3. Kassa, J.: J. Toxicol. Clin. Toxicol., 2002; 40, 803. Go to original source... Go to PubMed...
  4. Patočka, J. et al.: Vojenská Toxikologie. Praha,Grada Publishing, 2004, 179 s.
  5. Bajgar, J.: Historie používání chemických zbraní a jednání o jejich zákazu. Učební texty VLA Hradec Králové, Sv. 302, 1996, 112 s.
  6. Koplovitz, I., Stewart, J. R.: Toxicol. Lett., 1994; 70, 169. Go to original source... Go to PubMed...
  7. Kuča, K., Kassa, J.: Vet. Hum. Toxicol., 2004; 46, 15.
  8. Kuča, K., Bielavský, J., Cabal, J., Kassa, J.: Bioorg. Med. Chem. Lett., 2003; 13, 3545. Go to original source... Go to PubMed...
  9. Yang, G. Y et al.: Bull. Korean Chem. Soc., 2003; 24, 1368. Go to original source...
  10. Pang, Y. P. et al.: Chem. Biol., 2003; 10, 491. Go to original source...
  11. Kuča, K., Kassa, J.: J.Enzyme Inhib. Med. Chem., 2003; 18, 529. Go to original source... Go to PubMed...
  12. Ševelová, L., Kuča, K., Krejčová, G.: Toxicology, 2005; 207, 1. Go to original source... Go to PubMed...
  13. Eto, M.: Organophosphorus pesticides: Organic and Biological Chemistry. Cleveland, CRC Press Inc., 1976, s. 142.
  14. Koplovitz, I. et al.: Drug Chem. Toxicol., 1995; 18, 119. Go to original source... Go to PubMed...
  15. Cabal, J., Kuča, K., Kassa, J.: Bas. Clin. Pharmacol. Toxicol., 2004; 95, 81. Go to original source... Go to PubMed...
  16. Kuča, K., Patočka, J., Cabal, J.: J. Appl. Biomed., 2003; 1, 207. Go to original source...
  17. Bajgar, J., Jakl, A., Hrdina, V.: Biochem. Pharmacol., 1971; 20, 3230. Go to original source... Go to PubMed...
  18. Bajgar, J.: Sb. Věd. Prací LF UK (Hrade Králové), 1991; 34, 5.
  19. Sakurada, K. et al.: Neurochem. Res., 2003; 28, 1401. Go to original source... Go to PubMed...
  20. Kassa, J.: Čes. slov. Farm., 1998; 1, 46. Go to original source...
  21. Ševelová, L. et al.: J. Appl. Biomed., 2004; 2, 163. Go to original source...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.